GAO: FDA's Mifeprex approval 'consistent'

Share this article:
The Government Accountability Office said the FDA's approval process for Mifeprex, the RU-486 abortion pill, was “consistent with the processes for the other Subpart H restricted drugs,” and its post-market oversight also has been consistent with other such drugs that have special distribution and administration controls. 

The GAO report was issued in response to a congressional inquiry from Sen. Mike Enzi (R-WY) based on lingering suspicions that the drug's approval was politically coerced by the Clinton administration. The GAO said critics have questioned aspects of the Mifeprex approval process, including the reliance on historically controlled clinical trials that compare a drug's effects on a condition rather than to another drug or placebo.

Critics said that Mifeprex does not fit within the scope of Subpart H, which applies to drugs that treat serious or life-threatening illnesses. And concerns have been raised about the agency's post-marketing oversight, including its response to deaths in women who took the drug. The GAO reports the FDA reviewed the NDA through three review cycles.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.